Peri-Transplant Management of JAK Inhibitor Therapy in Myelofibrosis

Am J Hematol. 2025 Feb;100(2):196-199. doi: 10.1002/ajh.27559. Epub 2024 Dec 12.

Authors

Ayalew Tefferi¹, Vincent T Ho²

Affiliations

¹ Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
² Department of Medical Oncology, Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

PMID: 39668604
DOI: 10.1002/ajh.27559

No abstract available

Keywords: GVHD; HSCT; myelofibrosis; ruxolitinib; splenectomy.

Publication types

Editorial